Effect of Creatine Supplementation on the Airways of Youth Elite Soccer Players

Andrew J Simpson¹, Sara Horne¹,², Peter Sharp³, Robert Sharps³, and Pascale Kippelen¹,²

¹Center for Human Performance, Exercise and Rehabilitation, College of Health & Life Sciences, Brunel University London, United Kingdom; ²Division of Sport, Health and Exercise Sciences, Dept. of Life Sciences, Brunel University London, United Kingdom; ³Watford Football Club, United Kingdom

Accepted for Publication: 7 February 2019
Abstract

Introduction. Owing to its well-established ergogenic potential, creatine is a highly popular food supplement in sports. As an oral supplement, creatine is considered safe and ethical. However, no data exist on the safety of creatine on lung function in athletes. The aim of this project was to evaluate the effects of a standard course of creatine on the airways of youth elite athletes.

Methods. Nineteen elite soccer players, aged 16-21yr, completed a stratified, randomized, double-blind, placebo-controlled, parallel-group trial. The creatine group (n=9) ingested 0.3 g/kg/d of creatine monohydrate (CM) for 1wk (loading phase) and 5 g/d for 7wk (maintenance phase), and the placebo group (n=10) received the same dosages of maltodextrin. Airway inflammation (assessed by exhaled nitric oxide, FE\textsubscript{NO}) and airway responsiveness (to dry air hyperpnoea) were measured pre- and post-supplementation. Results. Mild, unfavorable changes in FE\textsubscript{NO} were noticed by trend over the supplementation period in the CM group only (P=0.056 for interaction, η\textsuperscript{2}=0.199), with a mean group change of 9 ± 13 ppb in the CM group versus -5 ± 16 ppb in the placebo group (P=0.056, d=0.695). Further, the maximum fall in forced expiratory volume in 1 sec (FEV\textsubscript{1}) after dry air hyperpnoea was larger by trend post-supplementation in the CM group compared to the placebo group: 9.7 ± 7.5% versus 4.4 ± 1.4%, respectively (P=0.070, d=0.975). These adverse effects were more pronounced when atopic players only (n=15) were considered. Conclusion. Based on the observed trends and medium-to-large effect sizes, we cannot exclude that creatine supplementation has an adverse effect on the airways of elite athletes, particularly in those with allergic sensitization. Further safety profiling of the ergogenic food supplement is warranted.
Effect of Creatine Supplementation on the Airways of Youth Elite Soccer Players

Andrew J Simpson¹, Sara Horne¹,², Peter Sharp³, Robert Sharps³, and Pascale Kippelen¹,²

¹Center for Human Performance, Exercise and Rehabilitation, College of Health & Life Sciences, Brunel University London, United Kingdom; ²Division of Sport, Health and Exercise Sciences, Dept. of Life Sciences, Brunel University London, United Kingdom; ³Watford Football Club, United Kingdom

Abbreviated title: Creatine supplementation and lung health

Corresponding author:

Dr Pascale Kippelen
Center for Human Performance, Exercise and Rehabilitation
College of Health and Life Sciences
Brunel University London
Kingston Lane
Uxbridge, Middlesex
UB8 3PH
UK
pascale.kippelen@brunel.ac.uk

This study was supported by the Union of European Football Associations (UEFA), through its UEFA Research Grant Programme. Conflict of interest: None
Abstract

Introduction. Owing to its well-established ergogenic potential, creatine is a highly popular food supplement in sports. As an oral supplement, creatine is considered safe and ethical. However, no data exist on the safety of creatine on lung function in athletes. The aim of this project was to evaluate the effects of a standard course of creatine on the airways of youth elite athletes.

Methods. Nineteen elite soccer players, aged 16-21yr, completed a stratified, randomized, double-blind, placebo-controlled, parallel-group trial. The creatine group (n=9) ingested 0.3 g/kg/d of creatine monohydrate (CM) for 1wk (loading phase) and 5 g/d for 7wk (maintenance phase), and the placebo group (n=10) received the same dosages of maltodextrin. Airway inflammation (assessed by exhaled nitric oxide, FE\textsubscript{NO}) and airway responsiveness (to dry air hyperpnoea) were measured pre- and post-supplementation. Results. Mild, unfavorable changes in FE\textsubscript{NO} were noticed by trend over the supplementation period in the CM group only (P=0.056 for interaction, $\eta^2=0.199$), with a mean group change of 9 ± 13 ppb in the CM group versus -5 ± 16 ppb in the placebo group (P=0.056, $d=0.695$). Further, the maximum fall in forced expiratory volume in 1 sec (FEV\textsubscript{1}) after dry air hyperpnoea was larger by trend post-supplementation in the CM group compared to the placebo group: 9.7 ± 7.5% versus 4.4 ± 1.4%, respectively (P=0.070, $d=0.975$). These adverse effects were more pronounced when atopic players only (n=15) were considered. Conclusion. Based on the observed trends and medium-to-large effect sizes, we cannot exclude that creatine supplementation has an adverse effect on the airways of elite athletes, particularly in those with allergic sensitization. Further safety profiling of the ergogenic food supplement is warranted.

Keywords: creatine monohydrate; football; airway inflammation; airway hyperresponsiveness; exhaled nitric oxide; eucapnic voluntary hyperpnoea
Introduction

Creatine is one of the most popular food supplements used by athletes (1); it is used in a wide variety of sports and at all levels [e.g. about a third of English professional soccer players (2) and the same percentage of American children and adolescents (3) declare using the supplement]. The popularity of creatine stems from the fact that the ergogenic potential of creatine is supported by strong scientific evidence (1) and its mechanisms of action are well understood. Since the early 1990s (4), studies have consistently shown that creatine supplementation raises intramuscular creatine stores, thereby helping to maintain ATP availability during exercise and enhancing high-intensity (anaerobic) exercise capacity (1). That creatine is not prohibited by the governing bodies of sport (including the World Anti-Doping Agency), and is purported to be safe (1,5) likely contributes to its widespread use.

The recognized potential of creatine to stimulate muscle strength and power, to increase muscle volume/fat-free mass, and to stimulate recovery from exercise (5) make it particularly attractive in sports with repeated short bursts of high-intensity activity. Evidence of an ergogenic effect of the supplement has repeatedly been reported in team sports, including soccer (6). Further, in semi-professional soccer players, a standard, 8-wk course of creatine monohydrate (CM) supplementation has been reported to be safe (7). However, no study has so far evaluated the possible adverse effect of creatine on lung function in athletes. This is particularly striking considering that, in an animal model of asthma, creatine has been shown to exacerbate allergic-induced lung inflammation, airway remodeling and airway hyperresponsiveness (AHR) (8). Creatine is thought to initiate an important cellular signaling pathway in the airway epithelium that results, amongst others, in: an increase infiltration of inflammatory cells to the airways; an
increased number of mucus-synthesizing cells; and an upregulation of airway remodeling (9).

Similar features have been observed in bronchial biopsies of elite athletes (10,11), many of whom suffer from asthma/AHR (10-13).

Asthma is a chronic inflammatory disorder of the airways, with associated allergic sensitization, that is characterized by reversible airway obstruction and AHR to a wide range of stimuli (including exercise). In elite sports, asthma/AHR is the most common chronic medical condition, with an overall prevalence of ~8% (12). The distribution of asthma/AHR in sport is however largely skewed, with the highest prevalence rates observed in endurance sports and/or in disciplines performed in unfavorable environments (e.g. swimming or cross-country skiing) (12-14). Nonetheless, recent reports have highlighted that team sport players, such as soccer (15,16) and rugby players (17,18), may also commonly suffer from asthma/AHR. Given the high prevalence of asthma-related problems and the widespread use of creatine supplements in elite sport, it is important to identify any adverse effects that ergogenic food supplements may have on lung function in this population.

The aim of our study was therefore to evaluate the effects of a standard course of creatine supplementation on the respiratory health of youth elite athletes. Our hypothesis was that ingestion of a standard dose of creatine monohydrate for 8wk, in combination with intensive soccer-specific training, increases airway inflammation and airway responsiveness.
Methods

Study participants

Nineteen under 18 (U18) and nine under 21 (U21), non-smoking, male, elite soccer players from Watford Football Club (FC) Academy agreed to take part in this project. Participants completed a medical questionnaire before the start of the study to check that none were currently injured or on medication [except for asthma and/or exercise-induced bronchoconstriction (EIB)]. On enrolment, one participant disclosed doctor-diagnosed asthma and, based on skin prick testing (cf. methodology below), nineteen (68%) had evidence of atopy. The study was approved by the Research Ethics Committee from the School of Sport & Education, Brunel University London (#RE69-13). All participants gave informed, written consent before taking part.

Study design

A stratified, randomized, double-blind, placebo-controlled, parallel-group trial of creatine supplementation was conducted over 8wk during the first half of the English competitive season (Oct-Dec). Stratified randomization was used to ensure equal distribution between groups of: i) participants with allergic sensitization (atopy) or doctor-diagnosed allergic asthma and ii) U18 and U21 players. Atopy was assessed at study entry by standard skin prick test (19), with the following allergens tested: house dust mite, timothy grass, silver birch, dog and cat hair. In line with current international recommendations (19), wheal diameters ≥3 mm were considered as positive.
All players abstained from caffeine and alcohol on the day of the tests, from exercise for at least 4 hours, and from anti-histamines for 72 h. To control for diurnal variation in lung function, all tests were conducted in the morning / early afternoon.

**Supplementation**

Participants were randomized into groups by an independent third party, using a random number generator. Allergic and non-allergic players, as well as U18 and U21 players were allocated, in equal numbers, to the creatine and placebo groups. A typical creatine monohydrate (CM) supplementation protocol was followed (1), whereby participants ingested 0.3 g/kg/d of CM (MyProtein, Informed Sports Range, 100% pure) during a 1-wk loading phase. The placebo group received the same dosage of maltodextrin (MyProtein, Informed Sports Range, 100% pure). The supplement was combined with 90 g of the participant’s usual protein drink (Maxiraw Protein Complex; 60% whey protein concentrate, 20% soy protein isolate, 20% micellar casein) provided to the players at Watford FC Academy, and ingested in four daily 150 ml intakes. This was followed by a 7-wk maintenance phase during which players ingested 5 g/day of CM, or of placebo, mixed up in 30 g of protein drink, and taken at the end of their daily training session or after games (at the weekend). To ensure adherence, the protein with supplement drinks were prepared daily by the Head Academy Sport Scientist (PS) at Watford FC Academy and handed out directly to the players at the required times (except on Sundays, when players were provided with shakers to take home).

Body mass of the participants was measured using a calibrated electronic scale pre- and post-supplementation. Body composition was assessed via skinfold measurement. In line with the
International Society for the Advancement of Kinanthropometry (ISAK), eight sites (i.e. tricep, sub-scapular, bicep, iliac crest, supra-spinal, abdominal, front thigh and medial calf) were measured. All measurements were taken by a Level 1 ISAK qualified researcher (with an average technical error of measurement of $1.50 \pm 0.31\%$).

Diet was not standardized, but participants were asked not to change their dietary habits during the course of the study. None of the players declared using creatine supplements in the three months prior to the study.

Daily record of asthma symptoms, upper or lower respiratory tract infection symptoms, use of asthma reliever medication (salbutamol), and other potential side effects (e.g. muscle cramps, musculo-skeletal injury, gastro-intestinal discomfort) were logged for all players.

**Training programme**

This research did not interfere with the training schedule devised by the players’ coaches. The 8-wk training programme included $\sim 11$ h *per week* of soccer specific training (i.e. technical and tactical exercises), with little strength and conditioning work ($\sim 1$ session of 50 min *per week*). As part of the Football League Youth Alliance, the U18 team had regular match fixtures over the course of the trial. Further, some the U21 players played for Watford FC first team (which, at the time of the study, was competing in the English Football League Championship).
Lung health assessment

All the tests below were performed twice: once before and once after the 8wk supplementation period.

Airway inflammation. Fractional nitric oxide in exhaled breath (FeNO) was measured at rest using NIOX VERO (Aerocrine, Solna, Sweden) and was used as a non-invasive marker of airway inflammation (20). Players were asked to refrain from exercising, eating and drinking for an hour prior to the FeNO measurements (21). As per standard recommendations (21), at least two measurements agreeing within 10% of each other were recorded, and the mean of the two values were calculated and used for analysis.

Lung function. Standard spirometry was performed at rest in all players using the MicroLoop spirometer (Micromedical, Kent, UK) to determine baseline lung volume and expiratory flow rates. In accordance with the international recommendations (22), at least three technically acceptable forced vital capacity (FVC) manoeuvres were performed (up to a maximum of eight), with a minimum of two reproducible recordings [difference ≤150 ml for forced expiratory volume in 1 sec (FEV₁) and FVC]. The highest FEV₁ and FVC readings were kept for analysis. Forced expiratory flow between 25 and 75% of FVC (FEF_{25-75}) was taken from the reproducible maneuver with the highest sum ‘FEV₁+FVC’. The highest peak expiratory flow from all acceptable maneuvers was kept for analysis. Predicted values were calculated from the GLI-2012 equations (23).

Airway hyperresponsiveness (AHR). A standard 6-min eucapnic voluntary hyperpnoea (EVH) test with dry air was used to estimate the degree of airway responsiveness. The test was performed on a commercially available system (EucapSys, SMTEC, Nyon, Swiss) and involved
6 min of heavy breathing of a dry gas mixture containing 5% CO₂, 21% O₂, and balance nitrogen (24). Pre-supplementation, the target ventilation (Vₑ) was set at 85% of predicted maximum voluntary ventilation (MVV) (24), calculated as resting FEV₁ multiplied by thirty. Post-supplementation, the target Vₑ was set at the achieved level during the initial test. Participants failing to achieve the minimal recommended threshold of 60% MVV (24) were noted and discussed in the results section. Prior to, and at 2, 5, 10, 15 and 20 min of recovery, FVC maneuvers were performed in duplicate. The best FEV₁ from reproducible measurements were kept for analysis. The maximal fall in FEV₁ post-EVH (expressed as % difference from baseline) was calculated as an index of airway responsiveness. A test was considered positive for EIB if FEV₁ fell by ≥10% from baseline over two consecutive time points (24).

Data analysis

Sample size. FₑNO was the primary outcome measure. The statistical power was set at 80% and the alpha level at 5%. To detect a 10 ppb difference in FₑNO between the CM and placebo groups post-supplementation [in non-inflamed airways, a change of 10 ppb being considered clinically meaningful (20)], with a within-group standard deviation of 6 ppb and a ratio of control to experimental participants of one, we calculated that a sample size of 14 players would be required (i.e. seven players per group). Taking account of an estimated drop-out rate of 30%, a minimum of twenty players was required.

Statistical analysis. Normal distribution was examined using the Shapiro-Wilk test. Data was analyzed using unpaired t-tests for between-group comparisons at the start of the trial and for changes over the supplementation period (Δ values). Two-way repeated measures analysis of
variances (RM-ANOVA), with ‘group’ and ‘time’ as main factors, were used to test between- and within-group differences during the trial. $F_{E\text{NO}}$ data had skewed distribution. As RM-ANOVA are robust and can tolerate data that is non-normally distributed with only a small effect on the Type I error rate, the statistical test was however retained. Spearman correlation coefficient was calculated to determine the relationship between baseline $F_{E\text{NO}}$ and change in $F_{E\text{NO}}$ following supplementation with CM. Considering that some previous investigations indicated that the deleterious effects of creatine may be specific to sensitized animals (8), post-hoc analyses were conducted (following the same procedures as described above) in atopic players only ($n=7$ in the CM group and $n=8$ in the placebo group). The significance level was set at $P<0.05$. A trend for statistical significance was deemed at $P<0.10$. Effect size was calculated via partial eta-squared values ($\eta^2$) for ANOVA and Cohen’s $d$ for $t$-tests. The magnitude of effect sizes was classified as small, medium and large for $\eta^2 > 0.01$, 0.06 and 0.14, respectively, and for $d > 0.2$, 0.5 and 0.8, respectively (25). Data were analyzed with SPSS 24 for Windows (SPSS, Chicago, IL). Unless otherwise stated, data are presented as group mean values $\pm$ SD.


Results

Participant characteristics

Twenty-eight players (19 U18 and 9 U21) were initially recruited, of whom nineteen completed the study. Details regarding participant withdrawals are provided in the CONSORT diagram (Figure 1). The only player with doctor-diagnosed asthma (treated by inhaled corticosteroids and inhaled beta2-agonist at the time of the study) withdrew due to an asthma exacerbation prior to randomization. Out of the nineteen players who completed the full trial (13 U18 and 6 U21), nine were in the CM group and ten in the placebo group.

At study entry, participants were aged 17.4 ± 1.6 yr, had a stature of 178.3 ± 5.6 cm and a body mass of 73.7 ± 5.3 kg. No group differences were noted for age or anthropometry (Table 1).

Eight weeks of CM or placebo supplementation did not significantly change the body mass of the players (P=0.421): in the CM group 75.7 ± 4.6 kg pre- versus 75.7 ± 4.6 kg post-supplementation, and in the placebo group 72.0 ± 5.5 kg pre- versus 72.3 ± 5.5 kg post-supplementation. A significant time effect was however noticed for body composition (P=0.002, $\eta^2=0.436$), with the sum of eight skinfolds reduced from 64 ± 15 mm to 61 ± 15 mm post-supplementation (and no group or interaction effect). The relative reduction in skinfold thickness was of 5.5 ± 5.0% in the CM group and of 4.4 ± 6.1% in the placebo group (P=0.678).

Fifteen (79%) players were atopic (Table 1), with grass being the most common allergen players were sensitized to. Twelve (63%) players were positive to grass, six (32%) to house dust mite, five (26%) to dog hair, five (26%) to cat hair, and two (11%) to silver birch.

One participant reported minor gastro-intestinal discomfort during the supplementation period; he was in the CM group. None of the other players reported any side effects from ingesting the
supplements. Two players reported a history of respiratory symptoms on exertion (i.e. chest tightness with/without cough) (Table 1), with one assigned to the CM group; neither of them reported an exacerbation of these symptoms or usage of asthma drugs over the supplementation period.

\[ F_{E \text{NO}} \]

The RM-ANOVA revealed no group or time effect for \( F_{E \text{NO}} \), but there was a trend for an interaction effect, with a \( P \) value of 0.056 and a \( \eta^2 \) value of 0.199 (the latter indicating a large effect size). Post-hoc tests showed that \( F_{E \text{NO}} \) did not significantly change over the supplementation period in the placebo group (\( P=0.374 \)), but there was a trend, with a medium effect size, for an increase in the CM group (\( P=0.071, d=0.695 \)) (Figure 2). A statistical trend, with a large effect size in the direction of an unfavorable change in \( F_{E \text{NO}} \) following CM (\( \Delta F_{E \text{NO}} = 9 \pm 13 \) ppb) compared to PLA (\( \Delta F_{E \text{NO}} = -5 \pm 16 \) ppb) was also observed (\( P=0.056, d=0.950 \)) (Figure 3). A significant positive relationship was noted between baseline \( F_{E \text{NO}} \) and \( \Delta F_{E \text{NO}} \) in the CM group (\( r_s^2=0.460, P=0.045 \)).

\[ \text{Resting lung function} \]

Resting lung function was normal (i.e. > lower limit of normal) in all the players, except one (Table 1, ID#14). This U18 player reported respiratory symptoms during strenuous exercise and had a family history of asthma, but no previous doctor diagnosis of asthma and/or EIB. No statistically significant differences in resting spirometry were observed between groups and/or
times (i.e. pre- to post-supplementation) (Table 2). While there was a trend for athletes in the CM group to have a larger resting FVC ($P=0.053$, $\eta^2=0.203$), this trend disappeared when the data was normalized for age, stature and ethnicity (FVC % pred.) (Table 2).

Airway hyperresponsiveness

During the EVH tests, players sustained a mean $V_E$ of $114 \pm 23 \text{ L} \cdot \text{min}^{-1}$ pre- and $115 \pm 25 \text{ L} \cdot \text{min}^{-1}$ post-supplementation in the CM group, and $94 \pm 18 \text{ L} \cdot \text{min}^{-1}$ pre- and $96 \pm 17 \text{ L} \cdot \text{min}^{-1}$ post-supplementation in the placebo group. The statistical trend in the direction of a greater $V_E$ in the CM compared to the placebo group ($P=0.063$; $\eta^2=0.188$) disappeared when the data was expressed as % of predicted MVV ($P=0.514$). $V_E$ was $71 \pm 10\%$ of predicted MVV pre- and $73\pm 11\%$ of predicted MVV post-supplementation for the CM group versus $68 \pm 13\%$ of predicted MVV pre- and $69 \pm 13\%$ of predicted MVV post-supplementation for placebo group. The supplementation had no impact on $V_E$ (i.e. no time or interaction effect). Three U18 players were unable to reach the minimum target $V_E$ of $\geq 60\%$ of predicted MVV pre-supplementation (with recorded $V_E$ at 59, 58 and $37\%$ of predicted MVV). Post-supplementation, two of these players reached the minimum threshold, while the latter only managed $40\%$ of predicted MVV.

The RM-ANOVA revealed no significant group or time effect on the maximum fall in FEV$_1$ post-EVH, but a trend for an interaction effect was noticed ($P = 0.086$ and $\eta^2 = 0.163$, large effect size). Post-hoc tests showed no significant changes in the fall in FEV$_1$ over the supplementation period in the CM group but a trend, with a medium effect size, for a reduced fall in FEV$_1$ in the placebo group ($P=0.060$, $d=0.679$) (Figure 4). Further, the fall in FEV$_1$
recorded post-supplementation was larger by trend, with a large effect size, in the CM group (9.7 ± 7.5%) compared to the placebo group (4.4 ± 1.4%) (P=0.070, d=0.975) (Figure 4).

At an individual level, three players (Table 1, ID#2,8&14) had a ≥10% fall in FEV₁ over at least two consecutive time points after EVH (consistent with a diagnosis of EIB) pre-supplementation; two of these players (both under CM) had also a sustained fall in FEV₁ post-supplementation (Figure 4). None of the three players with a positive EVH test had a history of asthma and/or EIB, but they all had abnormally high FeNO values (Table 1). The player who was positive for EIB pre-supplementation but negative post-supplementation (Table 1, ID#14) was the one who had an abnormally low lung function at rest (at both time points) and who reported respiratory symptoms during exercise; his data were consistent with a diagnosis of mild asthma. Another player in the CM group who reported occasional respiratory symptoms during exercise (Table 1, ID#9) had a borderline response to EVH (i.e. 9% fall in FEV₁ pre-supplementation and a non-sustained 11% fall post-supplementation) and markedly increased FeNO levels at both time points (84 and 96 ppb pre- and post-supplementation, respectively); his overall profile was therefore suggestive of mild, seasonal EIB. Altogether, this suggests that four out of the nineteen players (21%) had undiagnosed asthma and/or EIB.

**Post-hoc analysis in atopic participants (n=15)**

Similar to the whole group analysis, a RM-ANOVA conducted on FeNO measurements revealed a significant interaction effect in the atopic players (P=0.029 and η²= 0.317). Post-hoc tests showed a trend, with a large effect size, for FeNO to increase following supplementation with CM (P=0.072, d=0.824) and no change following placebo (P=0.248) (Figure 2). The statistical
trend for a between-group difference for the change in F\textsubscript{E}NO over the supplementation period was significant in atopic players \((P=0.029)\), with a large effect size \((d=1.272)\): \(\Delta F\textsubscript{E}NO = 12 \pm 14\) ppb in the CM group \textit{versus} -6 \pm 14 ppb in the placebo group (Figure 3).

Trend for within- and between-group differences in airway responsiveness reached statistical significance when atopic athletes only were entered into the analysis. For the maximum fall in FE\textsubscript{V}\textsubscript{1} post-EVH, the RM-ANOVA revealed a significant interaction effect \((P=0.027\) and \(\eta^2=0.323\)). \textit{Post-hoc} tests showed no significant changes in the fall in FE\textsubscript{V}\textsubscript{1} over the supplementation period in the CM group \((P=0.297)\) but a reduced fall in FE\textsubscript{V}\textsubscript{1} in the placebo group \((P=0.041, d=0.852)\) (Figure 4). Consequently, the change in AHR following the supplementation period was significantly different between the atopic players supplemented with CM (-1.3 \pm 3.0\%) and placebo (2.3 \pm 2.6\%) \((P=0.027, d=1.289)\). Further, the fall in FE\textsubscript{V}\textsubscript{1} recorded post-supplementation was significantly larger \((P=0.026, d=1.295)\) in the CM group (11.4 \pm 7.6\%) compared to the placebo group (4.5 \pm 1.5\%) in atopic players (Figure 4).

\textit{Discussion}

The aim of this study was to determine whether creatine supplementation in combination with intensive training increased airway inflammation and airway responsiveness in elite athletes. In soccer Academy players, trends for unfavorable changes in F\textsubscript{E}NO (an indirect marker of airway inflammation) were noticed after daily ingestion of CM for 8wk. A statistical trend in the direction of a greater fall in FE\textsubscript{V}\textsubscript{1} after dry air hyperpnoea – indicative of increased airway responsiveness – was also observed following CM supplementation compared to placebo. These effects were more pronounced when atopic individuals only were entered into the statistical
analysis. Therefore, our findings highlight possible adverse effects of the popular ergogenic food supplement on the airways of elite athletes, particularly in those with allergic sensitization.

The safety of creatine has widely been investigated in athletes through serum and urinary markers of metabolic, hepatic, renal and muscular function [e.g. (1,7)]. The general consensus is that, at the recommended dosage, creatine is safe (1,5). However, up to now, the effects of creatine supplements on lung function in athletes have not been assessed. In our study, trends (with medium-to-large effect sizes) for an increase in FeNO [a well-established marker for eosinophilic airway inflammation in humans (20)] were observed after 8wk of CM supplementation in a mixed group of atopic and non-atopic athletes. When atopic athletes (representing ~80% of the study population) were analyzed separately, statistical significance in favor of a larger increase in FeNO post-supplementation in the CM compared to the placebo group was noted. This is in keeping with data obtained in a murine model for allergic asthma (i.e. ovalbumin-treated mice) (8) that showed an increase in airway inflammation (as identified by infiltration of eosinophils and of pro-inflammatory cytokines within the airways) and occurrence of airway remodeling following 32 days of creatine supplementation. In chronically sensitized mice, low intensity aerobic exercise however reduced the exacerbatory effect of creatine (26).

The divergence in findings may be explained by the intensity of exercise. Indeed, there is a growing body of evidence of positive effects of regular physical activity on AHR in the general population (27) and on airway inflammation (28) and health-related quality of life in patients with asthma (29), yet a detrimental effect of repeated, intensive physical training on the airways of elite athletes (30,31).
At a cellular level, the pro-inflammatory effects of creatine could be explained by an up-regulation of an inflammatory cascade and by an increased infiltration of cells (including eosinophils) within the airways (9). In sensitized and non-sensitized mice, creatine supplementation has been shown to increase the epithelial expression of inducible nitric oxide synthase (9), i.e. the major determinant of FE\textsubscript{NO} (32). This could therefore explain the trend for an increased FE\textsubscript{NO} in the group supplemented with CM in our study. An up-regulation of the airway remodeling process was also noticed post-creatine supplementation in both groups of mice (i.e. sensitized and non-sensitized) (9). Signs of airway inflammation and remodeling (incl. goblet cells hyperplasia and over-expression of mucin) have previously been observed in bronchial biopsies of elite athletes, which were attributed to repeated exposure to high ventilation in unfavorable environments (10,11). Whether an additive inflammatory effect could have arisen due to the use of creatine supplements by some athletes is unknown.

In our study, the mild, unfavorable changes in FE\textsubscript{NO} were accompanied by a trend for increased airway responsiveness (as measured by the fall in FEV\textsubscript{1} post-EVH) in the group supplemented with CM compared to the placebo. This trend became significant when atopic athletes only were entered into the analysis. As the maximum fall in FEV\textsubscript{1} post-EVH was reduced in the atopic players following placebo but not CM supplementation, creatine could somewhat alter the natural course of airway responsiveness during a sporting season. It is not the first time that fluctuations in airway responsiveness are observed in elite athletes. Seasonal variability in the airway response to exercise has previously been noticed in elite runners (33) and elite swimmers (34), with AHR diminishing when changes in environmental conditions and/or reductions in training load limited the stress to the airways. While, in our study, the within- and between-
groups differences in the fall in FEV$_1$ post-EVH were small and did not reach clinical significance (i.e. no athletes under CM became positive for EIB post-supplementation), the duration of the intervention was relatively short (8 weeks). We cannot exclude that sub-clinical changes in airway responsiveness progress toward clinical changes (i.e. asthma or EIB) when atopic athletes ingest creatine chronically and/or do not adhere to the recommended dosage.

Asthma/AHR is the most common chronic medical condition in elite sport (12,35). However, it is largely misdiagnosed in professional (17,36) and recreational sports (37). In our study, we found objective evidence of asthma and/or AHR in about one in five youth players, but none had a medical history of asthma/EIB. In slightly younger (12-14 yr old) elite soccer players, 4 out of 19 (21%) players were positive for EIB when tested with EVH (15). These results therefore highlight the need for implementing screening programs for asthma/AHR in youth elite sport. This is all the more important in that cases of sudden fatal asthma exacerbations have been reported following competitive and recreational sporting activities, particularly in young (10-20 years old) males (38). Considering that three out of the thirteen U18 players (23%) in our study were not able to reach the minimum recommended ventilatory threshold of 60% predicted MVV (24) during the initial EVH test [an issue reported elsewhere (15)], there is probably a need to revisit and validate the minimum required $V_E$ for EVH when testing youth athletes.

While it is commonly accepted that creatine promotes muscle mass gains during resistance training (1,5), in our study, skinfold thickness was reduced post-supplementation in both groups (while body mass remained unchanged). This suggests that CM supplementation did not promote gains in muscle mass beyond the effects observed with soccer training alone. This may be
explained by the fact that i) creatine does not have a direct anabolic effect on protein synthesis (39,40) and muscle hypertrophy (41), ii) the benefits of the supplement seem mainly dependent upon an increased training workload (42) and iii) our groups were well matched for training load and players spent limited time in the gym during the supplementation period (~50 min of strength and conditioning per week). Beyond asking participants to maintain the same diet throughout the supplementation period, we were unfortunately not in a position to control their food intake; this could possibly have influenced muscle creatine content (43) and responses to the creatine supplement (5).

The strength of this study is the use of a rigorous methodological approach (i.e. a stratified, randomized, double-blind, placebo-controlled, parallel-group study design) in a difficult-to-reach sporting population (i.e. elite youth athletes). One limitation that comes with inclusion of elite athletes is the relatively large dropout rate (32%). Despite recruiting the entire U18 and U21 squads, only nine participants in the CM group and ten in the placebo group completed the full trial. Further, while we met our recruitment target (based on a priori sample size calculation), many of our data were largely spread (including our primary research outcome, F\textsubscript{E}NO). Having asked all our participants to refrain eating and drinking for 1 h before the F\textsubscript{E}NO measurements [based on the recommendations from the ATS/ERS (21)], we do not think that food and beverages could explain the large inter-individual differences in F\textsubscript{E}NO. That the three participants with the highest baseline F\textsubscript{E}NO values were atopic and presented the largest increase in F\textsubscript{E}NO post-CM supplementation suggest that individuals with underlying atopic airway inflammation may be more responsive to the effects of creatine. However, further studies (based around additional markers of airway inflammation) are now warranted to evaluate the clinical
significance of these findings. This is particularly necessary as a 20% increase in F\textsubscript{E}NO is usually recommended as cut-off (rather than 10 ppb increase used in this study) to establish the impact of an intervention in individuals with raised baseline values [i.e. F\textsubscript{E}NO >50 ppb (20)].

The large inter-individual difference in our primary research outcome (F\textsubscript{E}NO) could also have contributed to several of our P values not quite reaching the level of significance when analyzing our mixed group of atopic and non-atopic athletes. To overcome this limitation, two steps were taken: i) effect sizes were reported, with results suggesting that our intervention (i.e. CM supplementation) had moderate-to-large effects on F\textsubscript{E}NO and on the fall in FEV\textsubscript{1} post-EVH; and ii) post-hoc analyses were conducted on atopic players only (n=15), which confirmed (or even reinforced) the original trends. Therefore, in absence of any other human-based data, we cannot exclude a possible detrimental effect of CM on the airways of elite athletes, especially in the atopic ones.

**Conclusion**

In summary, mild unfavorable changes in F\textsubscript{E}NO were observed in youth elite soccer players, particularly in those with allergic sensitization, after a recommended 8-wk course of CM supplementation. This observation was coupled with a trend for the airways of athletes supplemented with CM to be slightly more responsive to dry air hyperpnoea compared to the placebo group post-supplementation. Until further work is performed on the safety profile of creatine supplements on lung function in humans, caution should prevail, and monitoring of the respiratory health of elite athletes regularly taking creatine supplements is advised.
Acknowledgments

The authors declare that the results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of the present study do not constitute endorsement by American College of Sports Medicine.

The authors would like to thank all the Watford FC Academy players who participated in this study and Mr Guy Farrier for his help with data collection. Andrew Simpson is currently affiliated to the Department of Sport, Health and Exercise Science, School of Life Sciences, University of Hull.

Funding

This study was supported by the Union of European Football Associations (UEFA), through its UEFA Research Grant Programme.

Conflict of interest

None
References


**Figure Captions**

*Figure 1.* Outline of the study design. FE\textsubscript{NO}, fractional nitric oxide in exhaled air

*Figure 2.* Fractional nitric oxide in exhaled air (FE\textsubscript{NO}) in youth elite soccer players before and after 8 weeks of creatine monohydrate (squares) or placebo supplementation (circles). Open symbols represent atopic players and closed symbols represent non-atopic players. Individual and mean values (with 95% confidence intervals) are shown. *Note.* When atopic players only were analyzed, the *P* value for within-group difference in the creatine group was 0.072.

*Figure 3.* Change in fractional nitric oxide in exhaled air (\(\Delta\) FE\textsubscript{NO}) in youth elite soccer players before and after 8 weeks of creatine monohydrate (squares) or placebo supplementation (circles). Open symbols represent atopic players and closed symbols represent non-atopic players. Individual and mean values (with 95% confidence intervals) are shown. *Note.* When atopic players only were analyzed, the *P* value for between-group difference was significant at 0.026.

*Figure 4.* Pre- and post-supplementation fall in forced expiratory volume in 1 sec (FEV\textsubscript{1}) after 6 min of eucapnic voluntary hyperpnoea (EVH) of dry air in youth elite soccer players supplemented for 8 weeks with creatine monohydrate (squares) or a placebo (circles). Open symbols represent atopic players and closed symbols represent non-atopic players. Individual and mean values (with 95% confidence intervals) are shown. *Note.* When atopic players only were analyzed, the *P* value for within-group difference in the placebo group was significant at 0.041, and the between-group difference.
Table 1. Characteristics of study participants.

<table>
<thead>
<tr>
<th>ID#</th>
<th>Age (yr)</th>
<th>Team</th>
<th>Body mass (kg)</th>
<th>Stature (cm)</th>
<th>FEV&lt;sub&gt;1&lt;/sub&gt; (%)</th>
<th>FVC (%)</th>
<th>Atopy</th>
<th>F&lt;sub&gt;e&lt;/sub&gt;NO (ppb)</th>
<th>Post-EVH</th>
<th>max FEV&lt;sub&gt;1&lt;/sub&gt; fall (%)</th>
<th>Respiratory symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>17</td>
<td>U18</td>
<td>79.2</td>
<td>180.5</td>
<td>102</td>
<td>107</td>
<td>-</td>
<td>14</td>
<td>6</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>16</td>
<td>U18</td>
<td>77.7</td>
<td>184.7</td>
<td>94</td>
<td>102</td>
<td>+</td>
<td>86</td>
<td>27</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>16</td>
<td>U18</td>
<td>74.6</td>
<td>187.3</td>
<td>104</td>
<td>106</td>
<td>+</td>
<td>23</td>
<td>8</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>16</td>
<td>U18</td>
<td>77.0</td>
<td>176.5</td>
<td>121</td>
<td>116</td>
<td>+</td>
<td>18</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>16</td>
<td>U18</td>
<td>68.5</td>
<td>175.5</td>
<td>102</td>
<td>96</td>
<td>+</td>
<td>20</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>17</td>
<td>U18</td>
<td>68.4</td>
<td>168.3</td>
<td>93</td>
<td>99</td>
<td>+</td>
<td>25</td>
<td>5</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>21</td>
<td>U21</td>
<td>79.3</td>
<td>184.5</td>
<td>115</td>
<td>120</td>
<td>-</td>
<td>18</td>
<td>5</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>19</td>
<td>U21</td>
<td>74.9</td>
<td>179.3</td>
<td>101</td>
<td>97</td>
<td>+</td>
<td>79</td>
<td>19</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>18</td>
<td>U21</td>
<td>81.5</td>
<td>183.5</td>
<td>108</td>
<td>110</td>
<td>+</td>
<td>84</td>
<td>9</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>17.3</td>
<td>NA</td>
<td>75.7</td>
<td>180.0</td>
<td>104</td>
<td>106</td>
<td>NA</td>
<td>40.8</td>
<td>9.1</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>1.7</td>
<td>NA</td>
<td>4.6</td>
<td>5.9</td>
<td>9</td>
<td>8</td>
<td>NA</td>
<td>31.9</td>
<td>8.3</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>16</td>
<td>U18</td>
<td>73.8</td>
<td>184.3</td>
<td>97</td>
<td>91</td>
<td>+</td>
<td>14</td>
<td>7</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>17</td>
<td>U18</td>
<td>70.7</td>
<td>173.0</td>
<td>114</td>
<td>104</td>
<td>+</td>
<td>21</td>
<td>9</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>16</td>
<td>U18</td>
<td>61.3</td>
<td>171.1</td>
<td>105</td>
<td>99</td>
<td>-</td>
<td>17</td>
<td>3</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>18</td>
<td>U18</td>
<td>66.0</td>
<td>170.8</td>
<td>98</td>
<td>98</td>
<td>-</td>
<td>35</td>
<td>4</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>16</td>
<td>U18</td>
<td>76.7</td>
<td>179.0</td>
<td>72</td>
<td>79</td>
<td>+</td>
<td>62</td>
<td>12</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>17</td>
<td>U18</td>
<td>67.0</td>
<td>170.5</td>
<td>109</td>
<td>100</td>
<td>+</td>
<td>17</td>
<td>11</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>17</td>
<td>U18</td>
<td>75.7</td>
<td>180.4</td>
<td>138</td>
<td>127</td>
<td>+</td>
<td>34</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>21</td>
<td>U21</td>
<td>78.1</td>
<td>177.5</td>
<td>103</td>
<td>100</td>
<td>+</td>
<td>18</td>
<td>4</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>19</td>
<td>U21</td>
<td>76.2</td>
<td>181.9</td>
<td>97</td>
<td>105</td>
<td>+</td>
<td>48</td>
<td>8</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>18</td>
<td>U21</td>
<td>74.4</td>
<td>179.0</td>
<td>93</td>
<td>91</td>
<td>+</td>
<td>18</td>
<td>3</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Mean 17.5 NA 72.0 176.8 103 99 NA 28.4 6.2 NA

SD 1.6 NA 5.5 5.0 17 12 NA 16.1 3.7 NA

*Note:* U18, under 18 years of age team; U21, under 21 years of age team; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; FeNO, fractional exhaled nitric oxide in exhaled air; EVH, eucapnic voluntary hyperpnoea; CM, creatine monohydrate group; SD,
standard deviation; NA, not applicable. None of the players had a medical history of asthma and/or of exercise-induced bronchoconstriction. No between-group differences were noticed at study entry.
Table 2. Resting lung function data in youth elite soccer players pre- and post-8 weeks of creatine monohydrate (CM) or placebo (PLA) supplementation

<table>
<thead>
<tr>
<th></th>
<th>CM (n=9)</th>
<th></th>
<th>PLA (n=10)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-CM</td>
<td>Post-CM</td>
<td>Pre-PLA</td>
<td>Post-PLA</td>
</tr>
<tr>
<td><strong>FEV₁ (L)</strong></td>
<td>4.56 ± 0.79</td>
<td>4.52 ± 0.84</td>
<td>4.06 ± 0.76</td>
<td>4.04 ± 0.75</td>
</tr>
<tr>
<td><strong>FEV₁ (% pred.)</strong></td>
<td>104 ± 9</td>
<td>103 ± 10</td>
<td>103 ± 17</td>
<td>101 ± 17</td>
</tr>
<tr>
<td><strong>FVC (L)</strong></td>
<td>5.43 ± 1.03$^s$</td>
<td>5.43 ± 1.03</td>
<td>4.57 ± 0.78</td>
<td>4.58 ± 0.74</td>
</tr>
<tr>
<td><strong>FVC (% pred.)</strong></td>
<td>106 ± 8</td>
<td>105 ± 8</td>
<td>99 ± 12</td>
<td>99 ± 12</td>
</tr>
<tr>
<td><strong>FEV₁/FVC (%)</strong></td>
<td>84 ± 4</td>
<td>83 ± 5</td>
<td>89 ± 6</td>
<td>88 ± 6</td>
</tr>
<tr>
<td><strong>PEF (L·sec⁻¹)</strong></td>
<td>9.73 ± 1.31</td>
<td>9.60 ± 1.35</td>
<td>9.05 ± 1.36</td>
<td>9.51 ± 1.51</td>
</tr>
<tr>
<td><strong>FEF₂₅₋₇₅ (L·sec⁻¹)</strong></td>
<td>4.66 ± 0.97</td>
<td>4.51 ± 1.10</td>
<td>4.62 ± 1.19</td>
<td>4.62 ± 1.36</td>
</tr>
</tbody>
</table>

*Note.* Values are means ± SD. FEV₁, forced expiratory volume in the first second; FVC, forced vital capacity; PEF, peak expiratory flow; FEF₂₅₋₇₅, forced expiratory flow between 25 and 75% of FVC; % pred., % of the predicted values (37); $^s$ trend for a higher pre-supplementation value compared to the placebo group ($P$=0.053).
Recruitment (n=28)
19 U18 and 9 U21

Withdraw

Pre-supplementation measurements (n=25)
Atpy, $F_{ENO}$, lung function, airway responsiveness

Randomization

Creatine (n=13)  Placebo (n=12)

Normal training regimen (n=25)
1wk loading + 7wk maintenance

Non-adherence (n=1)
Groin injury (n=1)
On loan (n=1)
Stopped training (n=1)

Withdrawn

Anterior cruciate ligament injury (n=1)
Broken rib (n=1)

Post-supplementation measurements (n=19)
$F_{ENO}$, lung function, airway responsiveness

n=9               n=10

Analysis
Figure 2

The figure shows a scatter plot comparing the FENO (ppb) levels between Placebo and Creatine groups before (Pre) and after (Post) treatment. The y-axis represents FENO levels, ranging from 0 to 125 ppb. The x-axis represents time points: Pre and Post for both Placebo and Creatine groups.

A significant trend is observed, with a p-value of 0.071 indicated by the annotation "P=0.071".
Figure 3

$P = 0.056$

$\Delta F_{ENo}$ (ppb)

Placebo     Creatine

$\Delta F_{ENo}$ (ppb)
Figure 4

Maximum fall in FEV$_1$ following EVH (%)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Creatine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$P=0.070$

$P=0.060$